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OBJECTIVES The objective of this study was to identify preprocedure patient factors associated with
percutaneous intervention costs and to examine the impact of these patient factors on
economic profiles of interventional cardiologists.
BACKGROUND There is increasing demand for information about comparative resource use patterns of
interventional cardiologists. Economic provider profiles, however, often fail to account for
patient characteristics.
METHODS Data were obtained from Duke Medical Center cost and clinical information systems for
1,949 procedures performed by 13 providers between July 1, 1997, and December 31, 1998.
Patient factors that influenced cost were identified using multiple regression analysis. After
assessing interprovider variation in unadjusted cost, mixed linear models were used to examine
how much cost variability was associated with the provider when patient characteristics were
taken into account.
RESULTS Total hospital costs averaged $15,643 (median, $13,809), $6,515 of which represented
catheterization laboratory costs. Disease severity, acuity, comorbid illness and lesion type
influenced total costs (R2  38%), whereas catheterization costs were affected by lesion type
and acuity (R2  32%). Patient characteristics varied significantly among providers.
Unadjusted total costs were weakly associated with provider, and this association disappeared
after accounting for patient factors. The provider influence on catheterization costs persisted
after adjusting for patient characteristics. Furthermore, the pattern of variation changed: the
adjusted analysis identified three new outliers, and two providers lost their outlier status. Only
one provider was consistently identified as an outlier in the unadjusted and adjusted analyses.
CONCLUSIONS Economic profiles of interventional cardiologists may be misleading if they do not adequately
adjust for patient characteristics before procedure. (J Am Coll Cardiol 2001;38:1416 –23)
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The demand for information about the cost and quality of
health care has increased dramatically. Health care purchas-
ers, providers and consumers alike seek information to help
them make better decisions in the health care market.
Provider profiling has emerged as an appealing method of
comparing the quality and cost of services (1). Initial
profiling efforts in interventional cardiology compared pa-
See page 1424
tient outcomes at the hospital level (2). However, within
institutions there can be great variability among physicians
in both resource use patterns and clinical outcomes. This
individual variability is of concern to patients seeking the
best care, to institutions striving to provide efficient, high
quality care and to payers trying to minimize health care
expenditures (1,3,4).
A major challenge in comparing procedural outcomes
among providers is to adequately adjust for baseline patient
characteristics that affect outcomes. Failure to account for
differences among providers in patient risk may bias profiles
in favor of providers who treat low risk patients (5–9). In
some areas, such as cardiac surgery, risk-adjustment models
for mortality are well developed and support ongoing
profiling efforts (10). Less is known about the impact of
patient mix on economic profiles. Available evidence sug-
gests that failure to account for variation among providers in
patient characteristics can distort provider comparisons (11).
Because the data and statistical resources needed to con-
struct economic profiles that account for patient risk far
exceed those required to create unadjusted profiles, it is
critical to determine whether unadjusted profiles can suffice.
In this study we examined the impact of baseline patient
characteristics on economic profiles of interventional cardi-
ologists. Specifically, we identified patient factors that in-
fluence catheterization laboratory and total hospital costs
associated with percutaneous coronary intervention. We
then assessed variability among providers in the cost of
interventions before and after adjusting for baseline charac-
teristics. The results of this study will contribute to the
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search for credible and feasible methods that can be used to
compare care cost and quality among providers.
METHODS
Patient population. All patients who had a percutaneous
coronary intervention (PCI) at Duke University Medical
Center between July 1, 1997, and December 31, 1998, were
eligible for this study. Patients were excluded if their clinical
records could not be linked to corresponding cost records or
if critical clinical and/or cost data were missing.
Data sources. Baseline clinical and demographic data were
obtained from the Duke Information System for Clinical
Computing. For each catheterization laboratory encounter,
the database includes demographic data, comorbid illnesses,
baseline severity of illness, preintervention procedures and
intervention characteristics. Data are entered by cardiology
fellows who are not associated with any particular attending
interventional cardiologist. Cost data were obtained from
the Duke Transition Accounting System. This system
contains detailed resource use at the intermediate product
level within each department (e.g., hours of care by inpa-
tient unit, number of diagnostic tests by type of test,
quantity of abciximab), along with fixed and variable unit
costs for each intermediate product. Total and variable costs
can be calculated for specific items, for each department and
for the entire admission.
Outcomes assessed. Both total hospital cost and variable
catheterization costs were examined in this study. Total
hospital cost includes variable and fixed costs for the
admission and reflects procedural resource use as well as
costs arising from any postprocedure complications. How-
ever, it also includes the cost of preprocedure care that may
have little to do with the procedure itself. Variable cathe-
terization costs include only the costs directly associated
with the procedure itself and, therefore, reflect resource use
that is most directly under the control of the provider.
Explanatory variables. In our investigation of patient fac-
tors that influence cost, candidate variables included base-
line characteristics previously found to affect either the
resource use or mortality associated with PCI (12–15). For
admissions with more than one interventional procedure,
baseline risk was determined by clinical status at the time of
the first procedure. Explanatory variables considered in-
cluded demographic characteristics (age, gender, race), co-
morbid illnesses (diabetes, prior stroke, chronic pulmonary
disease, peripheral vascular disease, cerebrovascular disease,
liver disease, renal disease), baseline severity of illness
(myocardial infarction [MI], ejection fraction, number of
diseased vessels, prior coronary bypass, prior PCI), and
intervention characteristics (number, location and percent
stenosis of attempted lesions). We also controlled for
pre-intervention diagnostic catheterizations. For multivessel
interventions, a hierarchical definition of target vessels was
developed after examining the cost and frequency of inter-
vention location combinations. The hierarchy included four
levels, the first of which was graft, followed by right
coronary artery, left anterior descending artery (LAD) or
left main and left circumflex artery. The attending interven-
tional cardiologist was included as an explanatory variable in
order to assess the extent to which individual providers
exerted an influence on cost.
Statistical analysis. Patient characteristics and costs were
first examined for the entire sample using descriptive statis-
tics. To assess the extent of variation in cost among
providers, before taking into account the patient’s baseline
characteristics, the providers were treated as random effects
in a linear model (Proc Mixed, SAS Institute, Cary, North
Carolina). Next, the influence of patient characteristics on
cost was explored using multiple linear regression models.
For variables with missing values (ejection fraction, number
of diseased vessels, congestive heart failure [CHF], race),
the value of missing was incorporated as a separate level in
a categorical variable. Finally, we incorporated patient
factors found in the linear regression analyses to influence
cost as fixed effects in mixed linear models to examine how
much variability in cost was associated with the provider
after adjusting for these patient factors. These mixed models
take into account the correlation among patients within
providers and in addition provide shrunken estimates that
adjust for variability arising from small provider sample sizes
(16).
In each of the statistical models, the dependent variable
was log-transformed so that residuals would be more nor-
mally distributed. The terms in these models are additive on
the log scale (e.g., log Cost  a  b1X1  b2X2  . . . ).
Thus, when exponentiated, the parameter(s) operate as
effect multiplier(s) on the outcome variable (total hospital
cost, variable catheterization cost). For example, the pres-
ence of a certain baseline characteristic with a multiplier of
1.1 signifies a 10% increase in costs associated with that
variable. A provider multiplier 1.0 suggests that the
provider’s patients tended to consume more resources than
other providers’ patients, whereas a multiplier of 1.0
indicates that the provider’s patients had lower resource use.
A multiplier of 1.0 (corresponding to a parameter estimate
of 0.0) indicates that the provider performing the procedure
had no independent effect on cost.
RESULTS
Sample selection. A total of 2,445 hospitalizations at
Duke University Medical Center involved percutaneous
coronary interventions during the study period (July 1, 1997,
to December 31, 1998). Of these, 255 (10%) were excluded
Abbreviations and Acronyms
CHF  congestive heart failure
LAD  left anterior descending artery
MI  myocardial infarction
PCI  percutaneous coronary intervention
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because of incomplete data or because clinical data could not
be linked with cost data. We then restricted the sample to
the first admission of each patient during the study period
(n 1,957). Analyses are reported for the 13 providers with
caseloads of 50 procedures (n  1,949).
Overall patient characteristics. The mean age of patients
was 61 years (SD  12) (Table 1). Most patients were men
(65%) and white (83%). Over half had a history of MI, with
7% having an event in the 24 h preceding their procedure.
Of the patients, 11% had a low ejection fraction (40%)
and 19% had CHF. Most patients (81%) had single-vessel
disease. Prior revascularization was common; 21% of pa-
tients had a history of bypass surgery and 23% had under-
gone a previous PCI. Diabetes was the most common
comorbid illness (28%), followed by peripheral vascular
disease (13%), chronic obstructive pulmonary disease (8%)
and renal insufficiency (7%). Most interventions (69%)
targeted a single lesion, and 10% of interventions involved a
totally occluded vessel. The most frequently targeted vessels
were the right coronary artery and LAD (38% and 36%,
respectively). Of the interventions 10% involved a graft.
Resource use: Overall and among providers. Total hos-
pital cost averaged $15,643 (median, $13,809), $9,033
(58%) of which was variable (Table 2). Mean total length of
stay was 3.7 days (median, 3 days), with a mean postpro-
cedure stay of 2.4 days (median, 1 day). Variable catheter-
ization costs accounted for over two-thirds of variable cost,
followed by routine room cost (9%), intensive care unit cost
(5%) and emergency room cost (4%) (Table 2). Use of both
stents and abciximab was fairly high (82% and 73% of cases,
respectively) and together accounted for half of catheteriza-
tion expenses. Other major catheterization expenses were
for balloons and hospital-based labor.
Using the multiplier estimates from the random effects
models, median total and catheterization costs were calcu-
lated for each provider. Median total hospital costs ranged
among providers from $12,922 to $15,501 (Fig. 1). The
random effects model for total cost indicated that the overall
provider effect approached significance (p  0.09), but
accounted for little (2%) of the variation. The model
identified a low and a high outlier (providers F and K,
respectively, in Fig. 1). The provider effect on variable
catheterization costs was slightly stronger than for total cost,
with 3% of variation being explained (p  0.06). Median
variable catheterization costs ranged among providers from
$5,235 to $6,547 (Fig. 2). Two high-cost outliers (providers
K and M) and one low-cost outlier (provider J) were
identified. Underlying this variation in catheterization costs
was considerable variability in the use of stents and abcix-
imab. Abciximab use ranged from a low of 52% of cases to
a high of 90% of cases. Stent use was slightly less variable,
with rates ranging from 67% to 89% of cases.
Influence of patient characteristics on cost. Multiple
linear regression was used to identify baseline patient factors
that were associated with total cost and catheterization cost.
Patient characteristics associated with both higher total cost
and catheterization cost included MI (with higher cost for
more recent events), more attempted lesions, higher percent
stenosis and graft interventions (Table 3). Patients who had
prior PCIs tended to have lower costs. As anticipated, a
diagnostic catheterization performed before the procedure
increased both total cost and catheterization cost. Total cost
was also influenced by age, extent of disease and comorbid
Table 1. Baseline Patient Characteristics
Demographics
Age (yrs; mean  SD) 61  12
Gender (% male) 65
Race (% white)* 83
Severity of illness (% of patients)
MI
6 h 4
6–24 h 3
1–7 days 27
7 days 21
None 45
Ejection fraction*
30% 4
30–39% 7
40–55% 32
55% 57
Number of diseased vessels*
1 81
1 19
Prior coronary artery bypass graft 21
Prior PCI 23
Comorbid illness (% of patients)
CHF* 19
Creatinine
1.5 mg/dl 93
1.5–2 mg/dl 5
2 mg/dl 2
Peripheral vascular disease 13
Cerebrovascular disease 9
Diabetes 28
Chronic obstructive pulmonary disease 8
Intervention characteristics (% of patients)
Number of attempted lesions
1 69
2 23
3 6
3 2
Maximum percent stenosis
75% 19
95% 71
100% 10
Preintervention diagnostic catheterization
Prior to intervention (same admission) 43
During same catheterization laboratory visit as
intervention
13
Location(s)
Graft 10
Right coronary artery 38
LAD 36
Left circumflex artery 28
Left main artery 1
*Missing values: race, 14%; ejection fraction, 26%; multivessel disease, 3%; congestive
heart failure, 2%.
CHF  congestive heart failure; LAD  left anterior descending artery; MI 
myocardial infarction; PCI  percutaneous coronary intervention.
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illness: cost increased with ejection fractions 40%, renal
insufficiency, CHF and multivessel disease. Gender was
significant only in the catheterization model, with female
patients having higher costs. Overall, the models explained
38% of variation in total cost and 32% of variation in
catheterization cost.
Variation among providers in patient factors associated
with cost. There was significant variation among providers
in baseline patient factors found to influence cost (Table 4).
For example, the proportion of elderly patients ranged from
7% to 26%, the proportion of patients having their inter-
vention within 24 h of an MI ranged from 4% to 14%, the
proportion with a multilesion intervention ranged from 18%
to 44%, and the proportion of cases involving a totally
occluded vessel ranged from 6% to 28%.
Provider variation in cost after adjustment for patient
characteristics. Given the variability among providers in
both baseline patient characteristics and cost, we reexam-
ined the influence of provider on total cost and catheteriza-
tion cost after accounting for patient factors using mixed
linear models. After adjustment, total cost no longer varied
among providers (0.4% of variation explained; p  0.39)
(Fig. 3). In contrast, the overall provider effect on variable
catheterization costs persisted after taking into account
patient risk (3% of variation explained; p  0.06) (Fig. 4).
Furthermore, despite the small absolute size of the provider
effect, the pattern of variation among providers changed.
Two new high outliers (providers B and L) and one new low
outlier (provider I) were identified by the model. The two
providers who had been identified as high outliers in the
Table 2. Mean Variable and Total Cost, by Department*
Variable
Cost ($)
Percent of
Variable
Total
Cost ($)
Percent of
Total
Catheterization laboratory
Balloons 961 11 1,424 9
Stents 2,172 23 3,219 0
Abciximab 1,142 13 1,494 9
Guide catheters/wires 318 4 472 3
Contrast dye 481 5 713 5
Hospital-based labor 880 10 2,114 6
Other 561 6 832 4
Catheterization laboratory subtotal 6,515 72 10,268 66
Intensive care 457 5 975 6
Routine/stepdown care 753 9 1,791 12
Emergency 407 4 850 5
Pharmacy 238 3 406 3
Labs 179 2 378 2
Diagnostic tests/procedures 276 3 528 3
Respiratory therapy 95 1 244 2
Operating room 73 1 139 1
Other 40  1 64  1
Grand total 9,033 100 15,643 100
*Costs in 1998 U.S. dollars.
Figure 1. Provider variation in unadjusted total cost. Median unadjusted total cost (circles) and associated confidence interval (diamonds), as estimated
by the random effects model, are presented for each provider. The overall median is represented by the solid line. Data points and labels of outlier providers
are outlined with rectangles.
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unadjusted analyses lost their outlier status. Only one
provider (provider J) was consistently identified as a low
outlier in both the adjusted and unadjusted analyses.
DISCUSSION
This study examined the impact of risk-adjustment on
economic profiles of interventional cardiologists. Our results
suggest that economic profiles that fail to take into account
patients’ baseline characteristics may incorrectly identify
some providers as outliers, while failing to recognize true
outliers. Thus, unadjusted economic profiles cannot con-
tribute to efforts to understand and optimize resource use in
PCI.
Impact of patient factors on provider comparisons. The
importance of statistically adjusting cost for the influence of
patient characteristics stems from two factors. First, prepro-
cedural patient factors had a major effect on the use of both
catheterization laboratory and total hospital resources, ex-
plaining one-third of variation in the cost of each. Second,
the severity of illness of patients varied among providers. If
all providers treated a similar mix of patients, statistically
adjusting for patient characteristics would not be critical in
provider comparisons, regardless of the strength of associ-
ation of patient factors with cost. However, variation in
patient mix among providers is likely to exist in many
institutions owing to differences in providers’ experience,
skill, and willingness to attempt high-risk cases. Our find-
ings support the results of studies in other therapeutic areas
that examined the impact of statistical adjustment for
patient factors on interprovider comparisons of resource use
(7,11). Our results are also consistent with studies of the
impact of risk-adjustment on provider profiles of mortality
(6,8,17).
Previous research. This study represents the first analysis
of provider effect on PCI cost that appropriately accounts
for the correlation among patients within providers and for
the varying sample sizes for individual providers. One
previous analysis found a much larger provider effect on
total and catheterization costs (15). This divergent finding
could be due to several factors, including the method of
analysis, the small sample size and the fact that providers
from different practice settings were included (both
university-based and private practice).
Factors associated with cost. Ours is also the first study to
explore the major cost drivers for coronary intervention
patients since the widespread adoption of stents and GP
IIb/IIIa inhibitor therapy. We found that these two new
technologies accounted for almost half of catheterization
laboratory expenses. Consistent with earlier analyses of
percutaneous intervention costs, both total cost and cathe-
terization costs were significantly influenced by the charac-
teristics of patients undergoing the procedure (13–15,18). In
particular, variables reflecting disease severity, acuity, co-
morbid illness and lesion type influenced total costs,
whereas catheterization costs were primarily affected by
acuity and lesion type. It is important to note that several of
the important variables influencing total cost and most of
the factors affecting catheterization costs are not available in
administrative databases. Therefore, it appears unlikely that
profiles of physician costs could be appropriately adjusted
for patient risk using readily available claims data.
Use of economic profiles. The information provided by
this study is necessary but not sufficient to compare the
practice efficiency of individual providers. Ideally, risk-
adjusted economic profiles would be combined with clinical
outcomes, such as rates of target vessel revascularization,
MI, and death at six-month follow-up in order to assess the
relative benefits of various practice styles. Such an integrated
assessment of both resource use and patient outcomes is
needed to determine which (if any) changes in practice
Figure 2. Provider variation in unadjusted catheterization cost. Median unadjusted catheterization cost (circles) and associated confidence interval
(diamonds), as estimated by the random effects model, are presented for each provider. The overall median is represented by the solid line. Data points
and labels of outlier providers are outlined with rectangles.
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patterns would minimize cost while maintaining quality of
care. However, the economic profiles alone can provide
valuable objective information regarding interprovider dif-
ferences in resource use. As such, they can serve as a starting
point for discussions among providers about the range and
relative merits of alternative approaches to percutaneous
intervention cases.
Study limitations. Detailed cost and clinical data were
needed to construct the adjusted economic profiles in this
study. While we characterized patient risk as completely as
possible, some risk factors that may influence cost and
clinical outcome, such as lesion complexity, were not avail-
able in the clinical database. In addition, a small but
significant proportion of patients had to be excluded from
our study because of clinical or cost data that were invalid,
missing, or could not be linked. Integrated economic and
clinical data systems would significantly reduce the cost and
Table 3. Multiple Regression Analysis of Total Cost and Length of Stay (n  1,949)*
Explanatory Variable
Log Total Hospital Cost Log Variable Catheterization Cost
Multiplier† p Value Multiplier† p Value
Intercept 8,041 4,518
Age (per 10 yrs) 1.02 0.02 n/a n/a
Gender (reference  male) n/a n/a 0.94  0.001
MI (reference  none)  0.001  0.001
6 h 1.52 1.07  0.01
6–24 h 1.49 1.11
1–7 days 1.22 1.06
7 days 1.07 1.04
Ejection fraction (reference  55%)  0.001 n/a n/a
29% 1.15
30–39% 1.25
40–55% 1.03
Missing 1.09
Multivessel disease (reference  single) 0.002 n/a n/a
1 vessel 1.07
Missing 1.03
Prior PCI 0.87  0.001 0.89  0.001
CHF  0.001 n/a n/a
Yes 1.07
Missing 0.87
Creatinine (reference  1.5 mg/dl)  0.001 n/a n/a
1.5–2 mg/dl 1.11
2 mg/dl 1.23
Cerebrovascular disease n/a n/a n/a n/a
Diabetes n/a n/a n/a n/a
No. of attempted lesions (reference  1)  0.001  0.001
2 1.24 1.37
3 1.38 1.67
3 1.66 1.94
Maximum % stenosis (reference  75%)  0.001  0.001
95% 1.04 1.06
100% 1.18 1.22
Target vessel (reference  left circumflex artery only) 0.003  0.001
Graft 1.10 1.13
Right coronary artery 1.08 1.08
LAD/left main artery 1.04 1.03
Diagnostic catheterization preceding intervention 1.36  0.001 1.20  0.001
Concomitant diagnostic catheterization 1.10 0.003 n/a n/a
Model performance (R2) 0.38 0.32
*n/a  variable not in final model. †Exponentiated parameter estimates from log models.
Abbreviations as in Table 1.
Table 4. Range Among Providers in Baseline
Patient Characteristics
Characteristics Minimum Maximum
Sample size 50 302
Risk factors (% of patients)
Age 75 years 7 26
Diabetes 20 34
Creatinine 1.5 mg/dl 3 13
Severity of illness (% of patients)
CHF 12 23
Prior PCI 16 31
Multivessel disease 6 26
MI 24 h 4 14
Ejection fraction 40% 6 17
Intervention type (% of patients)
100% stenosis 6 28
Multilesion 18 44
Location  graft 3 15
Abbreviations as in Table 1.
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time lag associated with economic profiling. Timely results
are critical in the field of interventional cardiology owing to
the continual adoption of new devices and adjunctive
therapies.
Generalizability. Although this study clearly demonstrates
the importance of statistically adjusting economic profiles of
interventional cardiologists, the specific findings may not be
generalizable to other institutions or time periods. The
absolute magnitude of variation associated with providers in
this study was relatively small (5% of the total variation).
This may be due to the tendency of providers working
together at one institution to develop similar practice
patterns over time. Variation might be greater among
providers practicing in different institutions or based in
different settings (e.g., a mix of private practice and
university-based providers). The findings also reflect the
particular time period studied, which was after the wide-
spread adoption of both stents and abciximab at Duke
University Medical Center. With the recent evidence sug-
gesting eptifibatide may be an effective GP IIb/IIIa inhib-
itor in PCI, considerably more diversity in practice patterns
may develop.
Conclusions. This study demonstrates the perils associated
with economic profiling without statistical adjustment for
patient characteristics. Although it may be relatively inex-
pensive and tempting to compare provider resource use and
costs using unadjusted administrative data, the results may
be misleading and potentially harmful to quality-
improvement efforts. Payers and providers will need to
invest in integrated clinical and cost data systems so as to
have meaningful comparative outcomes data with which to
guide clinical practice.
Figure 3. Provider variation in adjusted total cost. Median adjusted total cost (circles) and associated confidence interval (diamonds), as estimated by the
mixed effects model, are presented for each provider. The overall median is represented by the solid line. No outlier providers were identified. For reference,
data points of outlier providers identified in the unadjusted analysis are outlined with rectangles.
Figure 4. Provider variation in adjusted catheterization cost. Median adjusted catheterization cost (circles) and associated confidence interval (diamonds),
as estimated by the mixed effects model, are presented for each provider. The overall median is represented by the solid line. Data points and labels of outlier
providers are outlined with ovals. For reference, data points of outlier providers identified in the unadjusted analysis are outlined with rectangles.
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